Love and Marriage in the Novels of Jane Austen

ジェーン・オースティンの小説6作品は、主に理想的な夫選びについて描かれている。『高慢と偏見』、『分別と多感』、『エマ』における結婚および結婚と財産との関係について分析。Jane Austen’s six novels, written at the end of the 18th and early 19th centuries, are mainly about the search for a suitable husband. This paper will discuss marriage and its connection to money and property in three of Austen’s novels: Pride and Prejudice, Sense and Sensibility and Emma. I will also contrast Austen’s portrayal of love with that of Emily Brontë’s in Wuthering Heights

人間嫌いに人でなし：魅力的とは言えない登場人物たち

ジェーン・オースティンは、作品名にもなっている主人公、エマについて、「私以外だれも好きになれそうにないヒロイン」と書いている。このように、文学作品では好感が持てるとは言い難い語り手や人物が登場する場合も多い。『嵐が丘』のヒースクリフ然り、さらには『ジーキル博士とハイド氏の怪事件』のハイド氏、『ロリータ』のハンバート・ハンバート、『華麗なるギャツビー』のジェイ・ギャツビー、『日の名残り』のスティーブンス、そして『ソーラー』のマイケル・ビアードもまた然りである。本稿は、2016 年10 月30 日に徳島大学で開催された第9 回Japan Writers Conference (JWC) で発表しており、今回は人から好かれにくい人々が登場する作品がどのように成功をおさめ、主人公が魅力的でないにもかかわらず、なぜ読者が物語に引き込まれるのかを考察する。“I am going to take a heroine whom no one but myself will much like,” wrote Jane Austen of her eponymous protagonist Emma. Literature is populated with narrators and main characters who are not likeable: Heathcliff (Wuthering Heights), Mr Hyde (The Strange Case of Dr Jekyll and Mr Hyde), Humbert Humbert (Lolita), Jay Gatsby (The Great Gatsby), Stevens (Remains of the Day) and Michael Beard (Solar). This paper, originally presented at the 9th Japan Writers’ Conference at Tokushima University on 30 October 2016, will examine how the novels in which these characters appear achieve success, and why we care what happens, despite the unlikeable protagonists

Antenatally diagnosed ADPKD

[Extract] Advances in antenatal ultrasonographyhave substantially improved the counseling of pregnantwomen.1�4With this advancement comes a diagnosticdilemma in the approach to antenatal diagnoses of cystickidney disease. The differential diagnosis of enlargedcystic echogenic kidneys includes autosomal dominantpolycystic kidney disease (ADPKD), autosomal recessivepolycystic kidney disease, renal cysts and diabetessyndrome, and other syndromic disorders

ESD Ideas: Arctic amplification's contribution to breaches of the Paris Agreement

The Arctic is warming at almost 4 times the global average rate. Here we reframe this amplified Arctic warming in terms of global climate ambition to show that without Arctic amplification, the world would breach the Paris Agreement's 1.5 and 2 ∘C limits 5 and 8 years later, respectively. We also find the Arctic to be a disproportionate contributor to uncertainty in the timing of breaches. The outsized influence of Arctic warming on global climate targets highlights the need for better modelling and monitoring of Arctic change

Earthquake Risk and U.S. Highway Infrastructure: Frequently Asked Questions

This report addresses frequently asked questions about the risk from earthquakes to highway systems, including bridges, tunnels, pavements, and other highway components. Particular attention is given to highway bridges, which often are the most vulnerable highway structures. The report also discusses federal and nonfederal actions to reduce seismic risk to the U.S. highway system

La asociación : revista de primera enseñanza: Año XI Número 541 - (07/07/23)

There have been few new therapies for patients with chronic kidney disease in the last decade. However, the management of patients affected by genetic kidney disease is rapidly evolving. Inherited or genetic kidney disease affects around 10% of adults with end-stage kidney disease and up to 70% of children with early onset kidney disease. Advances in next-generation sequencing have enabled rapid and cost-effective sequencing of large amounts of DNA. Next-generation sequencing-based diagnostic tests now enable identification of a monogenic cause in around 20% of patients with early-onset chronic kidney disease. A definitive diagnosis through genomic testing may negate the need for prolonged diagnostic investigations and surveillance, facilitate reproductive planning and provide accurate counselling for at-risk relatives. Genomics has allowed the better understanding of disease pathogenesis, providing prognostic information and facilitating development of targeted treatments for patients with inherited or genetic kidney disease. Although genomic testing is becoming more readily available, there are many challenges to implementation in clinical practice. Multidisciplinary renal genetics clinics serve as a model of how some of these challenges may be overcome. Such clinics are already well established in most parts of Australia, with more to follow in future. With the rapid pace of new technology and gene discovery, collaboration between expert clinicians, laboratory and research scientists is of increasing importance to maximize benefits to patients and health-care systems

The Evolving Role of Diagnostic Genomics in Kidney Transplantation

Monogenic forms of heritable kidney disease account for a significant proportion of chronic kidney disease (CKD) across both pediatric and adult patient populations and up to 11% of patients under 40 years reaching end-stage kidney failure (KF) and awaiting kidney transplant. Diagnostic genomics in the field of nephrology is ever evolving and now plays an important role in assessment and management of kidney transplant recipients and their related donor pairs. Genomic testing can help identify the cause of KF in kidney transplant recipients and assist in prognostication around graft survival and rate of recurrence of primary kidney disease. If a gene variant has been identified in the recipient, at-risk related donors can be assessed for the same and excluded if affected. This paper aims to address the indications for genomic testing in the context for kidney transplantation, the technologies available for testing, the conditions and groups in which testing should be most often considered, and the role for the renal genetics multidisci-plinary team in this process

Theory Designed Strategies to Support Implementation of Genomics in Nephrology

Background: Genomic testing is increasingly utilized as a clinical tool; however, its integration into nephrology remains limited. The purpose of this study was to identify barriers and prioritize interventions for the widespread implementation of genomics in nephrology. Methods: Qualitative, semi-structured interviews were conducted with 25 Australian adult nephrologists to determine their perspectives on interventions and models of care to support implementation of genomics in nephrology. Interviews were guided by a validated theoretical framework for the implementation of genomic medicine—the Consolidated Framework of Implementation Research (CFIR). Results: Nephrologists were from 18 hospitals, with 7 having a dedicated multidisciplinary kidney genetics service. Most practiced in the public healthcare system (n = 24), a large number were early-career (n = 13), and few had genomics experience (n = 4). The top three preferred interventions were increased funding, access to genomics champions, and education and training. Where interventions to barriers were not reported, we used the CFIR/Expert Recommendations for Implementing Change matching tool to generate theory-informed approaches. The preferred model of service delivery was a multidisciplinary kidney genetics clinic. Conclusions: This study identified surmountable barriers and practical interventions for the implementation of genomics in nephrology, with multidisciplinary kidney genetics clinics identified as the preferred model of care. The integration of genomics education into nephrology training, secure funding for testing, and counselling along with the identification of genomics champions should be pursued by health services more broadly

Cost-effectiveness of targeted exome analysis as a diagnostic test in glomerular diseases

Background: Despite the emergence of diagnostic and clinical utility evidence in nephrology, publicly funded access to genomic testing is restricted in most health care systems. To establish genomic sequencing as a clinical test, an evaluation of cost-effectiveness is urgently required. Methods: An economic evaluation, informed by a primary clinical study and available clinical evidence and guidelines in nephrology, was performed to evaluate the cost-effectiveness and optimal timing of exome sequencing (ES) in adults and children with suspected monogenic glomerular diseases compared with nongenomic investigations (NGIs). Six diagnostic strategies reflecting current practice and recommended models of care in Australia were modeled: (i) NGIs, (ii) late gene panel followed by ES, (iii) late ES, (iv) early gene panel, (v) early gene panel followed by ES, and (vi) early ES. Results: ES with targeted analysis achieved a diagnosis in 23 of 63 (36.5%) adults and 10 of 24 (41.6%) children. NGIs were estimated to diagnose 4.0% of children, with an average estimated cost of AU$6120 per child. Integrating ES as a first-line test in children was cost saving, with an incremental cost saving of AU$3230 per additional diagnosis compared with NGIs. In adults, NGIs was estimated to diagnose 8% of patients, with an average estimated cost of AU$1830 per person. In adults, integrating ES early resulted in an incremental cost per additional diagnosis of AU$5460 relative to NGIs. Conclusions: Early ES with targeted analysis was effective for diagnosing monogenic kidney disease, with substantial cost savings in children

Towards a framework for analysis of eye-tracking studies in the three dimensional environment: a study of visual search by experienced readers of endoluminal CT colonography.

Objective: Eye tracking in three dimensions is novel, but established descriptors derived from two-dimensional (2D) studies are not transferable. We aimed to develop metrics suitable for statistical comparison of eye-tracking data obtained from readers of three-dimensional (3D) “virtual” medical imaging, using CT colonography (CTC) as a typical example. Methods: Ten experienced radiologists were eye tracked while observing eight 3D endoluminal CTC videos. Sub-sequently, we developed metrics that described their visual search patterns based on concepts derived from 2D gaze studies. Statistical methods were developed to allow analysis of the metrics. Results: Eye tracking was possible for all readers. Visual dwell on the moving region of interest (ROI) was defined as pursuit of the moving object across multiple frames. Using this concept of pursuit, five categories of metrics were defined that allowed characterization of reader gaze behaviour. These were time to first pursuit, identi-fication and assessment time, pursuit duration, ROI size and pursuit frequency. Additional subcategories allowed us to further characterize visual search between readers in the test population. Conclusion: We propose metrics for the characterization of visual search of 3D moving medical images. These metrics can be used to compare readers’ visual search patterns and provide a reproducible framework for the analysis of gaze tracking in the 3D environment. Advances in knowledge: This article describes a novel set of metrics that can be used to describe gaze behaviour when eye tracking readers during interpretation of 3D medical images. These metrics build on those established for 2D eye tracking and are applicable to increasingly common 3D medical image displays